By Steven Reinberg
THURSDAY, March 2, 2017 (HealthDay News) -- An experimental drug may significantly reduce the and improve the appearance of moderate to severe , a new, preliminary trial finds.
Nemolizumab is a man-made, injectable antibody that acts against the protein that has been identified as playing a part in , the international team of researchers said.
"The treatments for [eczema] have been disappointing because of their lack of efficacy and the long-term side effects," said Dr. Doris Day, a dermatologist at Lenox Hill Hospital in New York City. She had no role in the study.
"There are also issues with compliance, since the products often need to be applied to broad areas multiple times a day," she added.
Since this is a chronic condition, continued treatment is usually needed to maintain results, Day explained.
"The goal is to find a non- treatment that is easy to follow, and with reliable results and minimal adverse effects," she said.